Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer

Thyroid cancer is the most common endocrine malignancy, affecting nearly 600,000 new patients worldwide. Treatment with the BRAF inhibitor sorafenib partially prolongs progression-free survival in thyroid cancer patients, but fails to improve overall survival. This study examines enhancing sorafenib...

Descripción completa

Detalles Bibliográficos
Autores principales: Mortensen, Anja Charlotte Lundgren, Berglund, Hanna, Hariri, Mehran, Papalanis, Eleftherios, Malmberg, Christer, Spiegelberg, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558458/
https://www.ncbi.nlm.nih.gov/pubmed/37803074
http://dx.doi.org/10.1038/s41598-023-43486-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558458/
https://www.ncbi.nlm.nih.gov/pubmed/37803074
http://dx.doi.org/10.1038/s41598-023-43486-z

Ejemplares similares